Botulinum toxin pharmacology, units and handling
Serotypes, SNAP-25 cleavage, recovery by terminal sprouting, why units do not convert between brands, and the basis of secondary non-response.
Botulinum neurotoxin is a bacterial protein produced by Clostridium botulinum. Seven principal serotypes are described, labelled A to G, distinguished by their antigenicity and by which component of the SNARE complex they cleave. Cosmetic and most therapeutic practice uses serotype A; serotype B has a smaller therapeutic role. The remainder are of laboratory rather than clinical interest, but their differences are informative because they explain why duration of effect varies.
Mechanism
The molecule consists of a heavy chain, which handles binding and internalisation, and a light chain, which is a zinc-dependent protease. Binding occurs at cholinergic nerve terminals. The toxin is internalised by receptor-mediated endocytosis, the light chain translocates into the cytosol in a pH-dependent step, and it then cleaves its target substrate.
For serotype A that substrate is SNAP-25. Removal of nine residues from the C-terminus is sufficient to prevent productive assembly of the SNARE complex, and without that assembly the acetylcholine-containing vesicle cannot fuse with the presynaptic membrane. Release is blocked; the muscle fibre is not stimulated.
Serotype E cleaves the same protein at a different site, removing a longer fragment, and its clinical effect lasts days rather than months. Serotype B cleaves synaptobrevin instead. The comparison makes the point that duration is a property of what the protease does to the substrate and how long the resulting fragment persists, not simply of dose.
Recovery
Recovery is not degradation of a depot. Two processes have been described. Sustained blockade for more than a few days provokes sprouting from the motor nerve terminal, and these sprouts form new functional contacts with the muscle fibre. Later, transmission returns at the original terminal and the sprouts are eliminated as redundant. Clinically this appears as a gradual return of movement rather than an abrupt one.
Units are product-specific
This is the single most consequential handling fact in the field. A “unit” is defined by each manufacturer’s own biological assay. The assays differ in method and in the reference material used, and the resulting units are not equivalent between products. There is no validated conversion factor between brands, and published ratios are approximations derived from comparative trials of specific indications, not interchangeable currency.
The practical rule is that a dose is meaningless unless the product is named alongside it. Records, consent documents and any figure quoted from the literature must specify which preparation the units refer to.
Storage and reconstitution principles
Preparations are supplied as vacuum-dried or lyophilised powder and stored according to the individual summary of product characteristics — refrigerated for most products, with some tolerating ambient storage. Reconstitution uses preservative-free or preserved sodium chloride as specified for the product.
Two principles govern reconstitution volume. Total units delivered determine the magnitude of effect at the target. Volume determines spread: for a fixed number of units, a larger diluent volume distributes the toxin across a wider field, which is undesirable where a neighbouring muscle must be preserved and occasionally exploited where a broad, superficial effect is intended. Vigorous agitation is avoided because the protein is subject to shear denaturation, and reconstituted product is used within the interval given by the manufacturer.
Immunogenicity and secondary non-response
A patient who responded initially and no longer does presents a differential: inadequate dose, displaced injection points, changed product, altered expectations, or genuine immunoresistance. True immunogenic failure involves neutralising antibodies to the toxin’s heavy chain and is reported as uncommon in cosmetic doses, but it is not theoretical — a 15-patient case series drawn from twelve sites documents clinical resistance in patients treated at cosmetic dose ranges.
The risk factors discussed in that literature are large cumulative dose, short retreatment intervals and booster injections within a few weeks of a full treatment. The corresponding handling principle is to use the smallest dose that achieves the intended effect and to avoid early top-ups, which is also the position most consistent with the wider aesthetic literature.
